DE-MDCT Predicts Regional Functional Improvement After Reperfused AMI
DE-MDCT Predicts Regional Functional Improvement After Reperfused AMI
复制标题
DE-MDCT 预测再灌注 AMI 后区域功能改善
DOI：
10.1016/j.jcmg.2019.08.017
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Ieda Masaki
中科院分区：
文献类型：
--
作者：
Watabe Hiroaki;Sato Akira;Sugano Akinori;Takaiwa Yui;Harunari Tomohiko;Aihara Hideaki;Fumikura Yuko;Hoshi Tomoya;Yoshida Kentaro;Nishina Hidetaka;Maruo Kazushi;Takeyasu Noriyuki;Noguchi Yuichi;Aonuma Kazutaka;Ieda Masaki
2020年2月：516- 31518置信区间[CI]：0.150至0.446; p< 0.001和OR：0.269; 95%CI：0.152至0.476; p< 0.001）。当共同调整时，HE是无功能改善的显著预测因子（OR：0.343; 95%CI：0.193至0.608; p< 0.001）。对比增强CMR已被广泛用于在无电离辐射或注射肾毒性造影剂的情况下评估心肌活力。然而，与对比增强CMR相比，MDCT可以在短的检查时间内进行，并且通常可用且易于进行，这一事实提供了重要的优势。我们发现，MDCT检测的TEH可以预测局部心肌功能的改善。因此，这将是有用的再灌注AMI后的危险分层。
FEBRUARY 2020: 516–3 1 518 confidence interval [CI]: 0.150 to 0.446; p< 0.001 and OR: 0.269; 95% CI: 0.152 to 0.476; p< 0.001, respectively). When co-adjusted, HE was a significant predictor of no functional improvement (OR: 0.343; 95% CI: 0.193 to 0.608; p< 0.001). Contrast-enhanced CMR is well established for the assessment of myocardial viability without ionizing radiation or injection of nephrotoxic contrast material. However, the fact that MDCT can be performed within a short examination time and is generally available and easily performed provides important advantages compared with contrastenhanced CMR. We showed that the TEH detected by MDCT might predict the improvement of regional myocardial function. Therefore, it would be useful for risk stratification following reperfused AMI.